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Abstract 
MicroRNAs (miRNAs) are a class of small 
regulatory RNAs (20-23 nucleotides long) that have 
been found to play a critical role in the wide 
spectrum of biological processes. These small 
endogenous noncoding RNAs are able to negatively 
regulate gene expression by pairing with the 3'-
untranslated region (3'-UTR) of their target mRNA. 
miR-150 is a short and single-stranded miRNA, 
encoded by a gene located at 19q13.33 in Homo 
sapiens, which is processed to two mature forms 
(miR-150-5p and miR-150-3p). It has proven to be a 
pivotal miRNA engaged in the development of 
hematologic malignancies, normal haematopoiesis, 
differentiation of B and T cells, and a number of 
tumours including breast, osteosarcoma, lung, 
gastric cancer and etc. 
Keywords 
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Identity 
Other names: MIRN150, hsa-mir-150 
HGNC (Hugo): MIR150 
Location: 19q13.33 
Local order 
chr19: 49500785-49500868 (according to GRCh38). 
Based on Mapviewer Genes on Sequence, genes 
surrounding the MIR150 on 19q13.33 includes: 
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DNA/RNA 
Description 
RNA polymerase II produces the primary miRNA 
transcripts (Lee et al., 2004) what will result in 
hairpin loop structures by microprocessor complex 
(Cai et al., 2004; Lee et al., 2003; Gregory et al., 
2006).  
The stem-loop structure has a two-nucleotide 
overhang at its 3' end and termed as a pre-miRNA 
(precursor-miRNA). Pre-miRNAs will be exported 
to cytoplasm through the nucleocytoplasmic shuttler 
Exportin-5 (XPO5), in an energy dependent 
mechanism (Auyeung et al., 2013; Murchison et al., 
2004).  
In the cytoplasm, the pre-miRNA hairpin is cleaved 
to a miRNA:miRNA* duplex by the 
endoribonuclease Dicer (Lund et al., 2006; Park et 
al., 2011).  
Potentially, either strand of the duplex could be a 
functional miRNA, however only one strand usually 
interacts with mRNA target through the RNA-
induced silencing complex (RISC) (Filipowicz et al., 
2008). The sequence of has-miRNA-150, through 
the above mentioned mechanism, will be transcribed 
to a stem-loop structure (Reuter et al., 2010) which 
finally will maturates to MIR150-5p and MIR150-
3p. 
Protein 
microRNAs are not translated into amino acids. 
Mutations 
Mutations have not been reported. 
Implicated in 
Megakaryocytopoiesis 
MIR150 drives megakaryocyte-erythrocyte 
progenitors (MEPs) differentiation toward 
megakaryocytes at the expense of erythroid cells, 
and the transcription factor MYB is a critical target 
of MIR150 in this regulation (Lu et al., 2008). 
Thrombopoietin ( THPO) down-modulates MYB 
expression through induction of MIR150 (Barroga et 
al., 2008). MIR150 is expressed in mature B and T 
cells and regulates their differentiation; MIR150 
blocks the transition of pro-B to pre-B cells (Xiao et 
al., 2007). 
Cell-cell signaling 
Some cells secrete miRNAs as cell-cell signaling 
molecules (intercellular/interorgan) (Azimzadeh et 
al., 2014). Human THP-1 cells selectively package 
MIR150 into active microvesicles in vitro. These 
secreted microvesicles are delivered specifically into 
human HMEC-1 cells and induce their migration as 
an inflammatory response (Zhang et al. 2010). 
Pancreatic Cancer 
MUC4, a member of Mucins family, is a 
glycoprotein upregulated in pancreatic tumors. 
Silencing of MUC4 results in the suppression of cell 
growth and metastasis in pancreatic tumors (Singh et 
al., 2004). The binding site of MIR150 is located at 
the 3' UTR of MUC4, which leads to the 
downregulation of MUC4 expression. The 
overexpression of MIR150 mitigates the malignant 
behavior of pancreatic cancer cells (Srivastava et al., 
2011). 
MIR150 (microRNA 150) Arjmand M 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(9) 319 
 
Colorectal cancer 
In a work aiming to figure out the altered miRNAs 
in colorectal cancer (CRC) through characterization 
of the miRNA profiles of serum exosomes, Ogata-
Kawata et al. has showed that the serum exosomal 
levels of seven miRNAs, including MIR150, were 
significantly higher in primary CRC patients 
compared to healthy controls, and were significantly 
down-regulated after tumor surgery (Ogata-Kawata 
et al., 2014). However, miRNA expression profiling 
using qRT-PCR assays in 1) normal colorectal 
tissues, 2) adenoma and 3) CRC, MIR150 was found 
low down-regulated in all three groups and tumour 
tissue had reduced levels of MIR150 expression 
compared with paired non-cancerous tissue (Ma et 
al., 2012). 
Esophageal cancer 
MIR150 expression is significantly lower in 
esophageal squamous cell carcinoma (ESCC) 
samples compared with the normal esophageal 
mucosa levels (P < 0.001) (Yokobori et al., 2013). It 
has been supposed that MIR150 suppresses tumor 
proliferation by degradation the Zinc finger E box 
binding homeobox 1 ( ZEB1). 
Gastric cancer 
The probability of survival in gastric cancer is 
significantly lower in patients with high expression 
levels of MIR150 (Katada et al., 2009).  
MIR150 increases the proliferation rate of gastric 
cancer cells by targeting the tumor-suppressor early 
growth response factor 2 (EGR2) (Wu et al., 2010). 
Breast cancer 
High levels of MIR150 have been found in breast 
cancer tissues.  
The application of MIR150 inhibitors against breast 
cancer cell lines leads to apoptosis. There is a highly 
conserved MIR150-binding motif at the 3'UTR of 
P2X7 receptor (P2RX7 ID: 41623> ); MIR150 
down-regulates the P2X7 protein levels and 
therefore causes the cancerous cells to escape from 
P2X7 pro-apoptotic control (Huang et al., 2013). 
Lung cancer 
Application of antisense oligonucleotide (ASO) 
against MIR150 in lung carcinoma cells A549 has 
induced the reduction of cell proliferation rates and 
increased apoptosis. Up-regulation of TP53 was 
detected after ASO treatment (Li et al., 2012). 
MIR150 is upregulated in lung cancer and correlates 
negatively with the expression of TP53 (Zhang et al., 
2013). MIR150 regulates the expression of TP53 
through binding to its 3'-UTR, thus inhibition of 
MIR150 leads to reduction of cell proliferation and 
increases apoptosis and expression of TP53. In 
another study, it was demonstrated that MIR150 
represses SRC Kinase Signaling Inhibitor 1 
(SRCIN1) which leads to the activation of the 
Src/focal adhesion kinase (PTK2 or FAK) and 
Src/Ras/extracellular signal-regulated kinase (ERK) 
pathway, and enhances the migration and 
proliferation rate of A549 cells (Cao et al., 2014). 
Moreover, GU XY et al. showed that the 
overexpression of MIR150 in non-small-cell lung 
cancer (NSCLC) is associated with alterations in the 
expression of human BRI1-associated receptor 
kinase 1 (BAK1), so that inhibition of MIR150 
reduces cell proliferation and promotes cell 
apoptosis (Gu et al., 2014).  
However, it has been argued that the expression level 
of MIR150 in patients with small-cell lung cancer 
(SCLC) is much lower than normal lung samples (Bi 
et al., 2014). 
Liver cancer 
It has been suggested that MIR150 could be a 
suitable candidate to discriminate tumoural versus 
normal human primary hepatocytes (Di Masi et al., 
2010).  
In addition, it has been confirmed that the 
overexpression of MIR150 downregulates MYB 
protein levels and causes a significant reduction of 
CD133+ cells and the suppression of cell 
growth/tumorsphere formation (Zhang et al., 2012).  
It is suggested that MIR150 may be engaged in the 
self-renewal of liver cancer stem cells through 
modulation of the downstream target MYB. 
Osteosarcoma 
A nearly 50-fold overexpression of MIR150 in 
osteosarcoma samples compared to normal 
osteoblasts, has been reported (Lulla et al., 2011). 
Upregulation of MIR150 may cause the down-
regulation of P2X7 receptor and therefore an 
uncontrolled growth of osteosarcoma cells. Other 
study has argued that MIR150 inhibits cell 
proliferation and metastasis in osteosarcoma and 
stimulates cell apoptosis by regulating the 
expression of SP1 (Li et al., 2015). Recently, it has 
been reported that MIR150 functions as a tumor 
suppressor in osteosarcoma partially by targeting the 
IGF2 mRNA-binding protein 1 (IGF2BP1) (Qu et 
al., 2016). 
Hepatocellular carcinoma 
In a recent attempt to identifying the role of miRNAs 
in hepatocellular carcinoma (HCC) progression, 
researchers have shown that there are low levels of 
miR-150-5p in cancerous samples, and determined 
that the inhibition of miR-150-5p has a drastic effect 
on hepatoma cell migration and invasion, whereas its 
overexpression shows reverse results (Li et al., 
2014). It was also confirmed that miR-150-5p 
inhibits the matrix metalloproteinase 14 (MMP14) 
expression in hepatoma cells. 
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Prostate cancer 
The high expression levels of MIR150 is positively 
correlated with tumor recurrence or metastasis 
(p=0.010) (Dezhong et al., 2015). It was shown that 
prostate cancer patients with high MIR150 
expression have significantly poorer overall survival 
and poorer disease-free survival compared those 
with low MIR150 expression. Furthermore, 
increased MIR150 expression might participate in 
the development and progression of human prostate 
cancer stem cells (CSC) via suppressing p27Kip1 
(CDKN1B ) (Liu et al., 2015). 
Intrahepatic cholangiocarcinoma 
MIR150 is significantly downregulated in 
intrahepatic cholangiocarcinoma (ICC) tissues; 
however its expression level in the blood samples of 
ICC patients is significantly higher than in controls 
(Wang et al., 2015). 
Burkitt lymphoma (BL) 
MIR150 is dramatically down-regulated in BL 
patients; MYB and Survivin (BIRC5) are the targetrs 
of MIR150 (Wang et al., 2014). In addition, MIR150 
can induce Epstein Barr virus-positive BL 
differentiation by targeting MYB (Chen et al., 2013). 
Cervical cancer 
Interacting with 3' UTR of FOXO4, MIR150 reduces 
FOXO4 expression level and thereby regulates 
several cell cycle- and apoptosis- related genes 
(CyclinD1 (CCND1), p27, BCL2L11 (BIM), and 
FASLG), and leads to cervical cancer cell growth 
and survival (J Li et al., 2015). 
Bladder cancer 
An in vitro investigation to figuring out the role of 
MIR150 in cells has shown that MIR150 functions 
as a tumor promoter in reducing chemo-sensitivity 
and promoting invasiveness of muscle-invasive 
bladder cancer cells via targeting programmed cell 
death 4 protein (PDCD4) (Y Lei et al., 2014). 
Epithelial ovarian cancer 
A significant low expression level of MIR150 have 
been reported in epithelial ovarian cancer (EOC) 
tissues and patients' serum (Vang et al, 2013; Shapira 
et al., 2014). MIR150 may function as a tumor 
suppressor and modulate EOC cell proliferation, and 
invasion by directly and negatively regulating Zinc 
Finger E-Box Binding Homeobox 1 (ZEB1) (Jin et 
al., 2014). 
Influenza 
Patients with severe A/H1N1 disease exhibited a 
significant over-expression of circulating MIR150 
than patients with milder disease, suggesting that the 
up-regulation of MIR150 is engaged with poorer 
outcomes of A/H1N1 infection (Morán et al., 2015). 
Acquired immune deficiency 
syndrome (AIDS) 
Down regulation of MIR150 during HIV infection 
and its lower level in CD4+ T cells of chronic HIV 
patients compared to healthy controls has been 
reported (Witwer et al., 2012; Swaminathan et al., 
2009).  
It has been speculated that the suppression of 
MIR150 promotes HIV-1 infection (X Wang et al., 
2009). HIV positive patients can be grouped based 
on the MIR150 levels of their peripheral blood 
mononuclear cells or their plasma, suggesting 
MIR150 as a new biomarker for HIV progression, 
therapy and resistance (Munshi et al., 2014). 
Dengue haemorrhagic fever (DHF) 
The downregulation of suppressors of cytokine 
signaling 1 (SOCS1) proteins through transfection of 
a MIR150 mimic into CD14(+) cells infected with 
DENV-2, suggests that augmented MIR150 
expression with depressed SOCS1 expression in 
CD14(+) cells is associated with the pathogenesis of 
DHF (RF Chen et al., 2014). 
Cardiovascular Diseases 
Low expression levels of MIR150 is associated with 
acute myocardial infarction, atrial fibrillation, 
dilated cardiomyopathy, ischaemic cardiomyopathy 
and various mouse heart failure models (Devaux et 
al., 2013; Liu et al., 2012; Topkara et al., 2011; Duan 
et al., 2013). MIR150 could be a better biomarker for 
HF than other markers used in clinic (Ellis et al., 
2013). MIR150 has a pivotal role as a regulator of 
cardiomyocyte survival during cardiac injury (Tang 
et al., 2015). Reduced circulating MIR150 levels are 
associated with poor survival in pulmonary arterial 
hypertension (Rhodes et al., 2013). 
Systemic sclerosis 
MIR150 may play an important role in the 
pathogenesis of Systemic Sclerosis (SSc) via 
overexpression of integrin β 3 (ITGB3) (Honda et 
al., 2013). MIR150 expression level is decreased in 
SSc fibroblasts and the treatment of normal 
fibroblasts with MIR150 inhibitor promotes the 
expression of integrin β3, phosphorylated SMAD3, 
and type I collagen. SSc patients with lower serum 
MIR150 levels show more severe clinical 
manifestations. 
Multiple sclerosis (MS) 
MIR150 is down-regulated in peripheral blood 
mononuclear cells and T cells from MS patients 
(Martinelli-Boneschi et al., 2012; Freiesleben et al., 
2016). 
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